<DOC>
	<DOCNO>NCT00563914</DOCNO>
	<brief_summary>The primary objective ass safety different dos ferroquine artesunate ( AS ) adult African patient uncomplicated malaria . The secondary objective assess activity reduce parasitemia pharmacokinetics ferroquine metabolite .</brief_summary>
	<brief_title>A Comparative Safety Activity Study With Ferroquine Associated With Artesunate Versus Amodiaquine Associated With Artesunate African Adult Patients With Uncomplicated Malaria</brief_title>
	<detailed_description>The study duration 30 day include 2 day screen period , 3 day treatment period follow-up period 25 day . Patients remain hospitalized 4 day .</detailed_description>
	<mesh_term>Malaria</mesh_term>
	<mesh_term>Amodiaquine</mesh_term>
	<mesh_term>Artesunate</mesh_term>
	<mesh_term>Artemisinins</mesh_term>
	<criteria>Body weight 50 kg 90 kg Body Mass Index &gt; 18 kg/m² Presence body temperature ≥ 37.5°C history fever within last 24 hour Monoinfection Plasmodium falciparum parasitemia within 100 200,000/microL Hypersensitivity quinoleines artesunate History presence clinically significant disease symptom , judgment investigator , might confuse interpretation safety efficacy information Splenectomized patient Laboratory parameter outside normal range Presence HBs antigen , antiHCV antibody antiHIV 1 &amp; 2 antibody Cardio vascular Electrocardiogram parameter outside normal value Presence criterion complicate malaria Permanent vomit Previous treatment within 5 time elimination halflife antimalaria agent market investigational drug ( include St John 's Wort ) within 14 day administration , within 5 time elimination halflife drug , whichever long , especially CYP3A 2D6 main substrate Positive result urine drug screen antimalaria agent ( aminoquinolines ) History drug alcohol abuse ( alcohol consumption &gt; 40 grams/day ; i. e. 2.5 beer 33cl 5 degree alcohol ) Intention use herbal medicine study period Immunization injection within last 15 day The information intend contain consideration relevant patient 's potential participation clinical trial .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>December 2009</verification_date>
	<keyword>Malaria</keyword>
</DOC>